Ledyard, CT, United States of America

John L La Mattina

This inventor holds 1 USPTO granted patent. Top assignee: Pfizer Corporation. Active years: 1983.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John L La Mattina. Retrieved from https://idiyas.com/inventor/john-l-la-mattina

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1983

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John L La Mattina: Innovator in Antisecretory Agents

Introduction

John L La Mattina is a notable inventor based in Ledyard, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as antisecretory agents. His work has implications for the treatment of gastric hyperacidity and peptic ulcers.

Latest Patents

La Mattina holds a patent for a series of compounds known as 2-Guanidino-4-heteroarylthiazoles. These compounds feature a heteroaryl substituent selected from thiazolyl, triazolyl, imidazolyl, and various derivatives. The novel compounds exhibit activity as histamine H₂ antagonists and are useful in treating gastric hyperacidity and peptic ulcers. Additionally, the patent describes pharmaceutical compositions containing these compounds and methods for their use in medical treatments.

Career Highlights

La Mattina is associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to focus on innovative solutions in drug development. His contributions have been instrumental in advancing therapeutic options for patients suffering from gastric conditions.

Collaborations

La Mattina has collaborated with Christopher A Lipinski, a fellow researcher in the pharmaceutical field. Their partnership has likely fostered advancements in the development of effective treatments.

Conclusion

John L La Mattina's work exemplifies the impact of innovation in the pharmaceutical industry. His patent for 2-Guanidino-4-heteroarylthiazoles represents a significant advancement in the treatment of gastric hyperacidity and peptic ulcers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…